A recent article by the Financial Times titled "UK brain monitoring start-up goes from teenage idea to $100mn funding" details the London-based company CoMind, a medical technology startup developing a noninvasive brain monitoring device. The article highlights Benchmark as CoMind's development and manufacturing partner for the innovative device.
CoMind’s technology, which uses low-powered infrared lasers to measure cerebral blood flow, intracranial pressure, and autoregulation, aims to transform patient care for those suffering from traumatic brain injuries and undergoing complex surgeries. It provides a safer alternative to traditional intracranial bolts, which require drilling into the skull and can lead to complications in up to 15 percent of cases. The device monitors vital brain metrics without invasive procedures by sending light through the skull and leveraging advanced signal processing. Recent advances in lasers and graphics processing units make this innovation possible, allowing for rapid data analysis in a compact, hospital-ready form factor.
“The brain is the most important organ that you have and yet it’s the least monitored at the patient bedside,” said CoMind founder James Dacombe in a recent Financial Times article. “We want this [brain monitoring] to become as common as having your blood pressure taken.”
Michael Tarnoff, a US surgeon and CoMind board member, commented, “None of this has ever been done before and it all holds the promise of dramatically changing care standards while reducing costs and improving outcomes.”
With over $100 million in funding and successful clinical trials completed in Barcelona and London, CoMind is now recruiting for its third US-based clinical trial to secure FDA approval.
The partnership seeks to leverage Benchmark's 40 years of expertise in developing and manufacturing medical devices. This expertise will be instrumental in scaling production and bringing this transformative technology to hospitals worldwide, potentially revolutionizing the way brain health is monitored and managed.
View the complete article here. This article requires a subscription to view.
